…by CD4 (<25 vs. ≥25 cells/mm3) and poor prognostic factors (BMI<18.5, HGB<8 g/dL, and recent hospitalization). To evaluate the effects of the intervention on longer-term outcomes, Kaplan-Meier estimates of the…
Please join us in remembering the extraordinary lives of Dr David A. Katzenstein and Dr James G. Hakim by leaving your message of condolence and sharing your stories, memories, and…
…metrics. We evaluated a novel point-of-care urine tenofovir (TFV) assay, using antibody-based technology, to measure adherence and its alignment with self-reported adherence and HIV seroconversion among AGYW. Methods: From August…
…and friends again, face-to-face. Our new conference venue is the Summit at the Seattle Convention Centre adjacent to the former Washington State Convention centre that you may remember from previous…
The ongoing More Options for Children and Adolescents Study (MOCHA; Clinicaltrials.gov NCT03497676) is the first to examine use of long-acting injectable (LA) antiretrovirals (ARV) (cabotegravir [CAB-LA] and rilpivirine [RPV-LA]) in…
…advanced HIV-infected adults screened out for TB using routine measures, outcomes in those who tested positive, and the effect of excluding LAM+ participants on trial outcomes. ACTG A5274 is a…